Elevance Health, Inc. (NYSE:ELV) Stake Decreased by Harbor Investment Advisory LLC

Harbor Investment Advisory LLC trimmed its holdings in Elevance Health, Inc. (NYSE:ELV) by 20.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,510 shares of the company’s stock after selling 387 shares during the quarter. Harbor Investment Advisory LLC’s holdings in Elevance Health were worth $557,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the business. Raelipskie Partnership acquired a new position in shares of Elevance Health during the third quarter valued at $26,000. PSI Advisors LLC acquired a new stake in Elevance Health in the third quarter worth about $27,000. Eastern Bank bought a new position in Elevance Health in the 3rd quarter valued at about $31,000. Dunhill Financial LLC increased its stake in Elevance Health by 57.8% during the 3rd quarter. Dunhill Financial LLC now owns 71 shares of the company’s stock valued at $37,000 after buying an additional 26 shares during the period. Finally, Peterson Financial Group Inc. bought a new stake in shares of Elevance Health during the 3rd quarter worth about $44,000. 89.24% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently commented on ELV shares. UBS Group lowered their price objective on shares of Elevance Health from $605.00 to $555.00 and set a “buy” rating on the stock in a research note on Friday, October 18th. Mizuho lowered their price target on Elevance Health from $585.00 to $505.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 5th. Barclays cut their price objective on Elevance Health from $622.00 to $501.00 and set an “overweight” rating for the company in a report on Tuesday, October 22nd. Raymond James set a $485.00 target price on Elevance Health in a report on Friday, October 18th. Finally, Royal Bank of Canada cut their price target on shares of Elevance Health from $585.00 to $478.00 and set an “outperform” rating for the company in a report on Friday, October 18th. One analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $536.53.

Elevance Health Trading Up 1.1 %

Elevance Health stock opened at $389.45 on Wednesday. Elevance Health, Inc. has a 52 week low of $362.21 and a 52 week high of $567.26. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.50 and a current ratio of 1.50. The firm has a market capitalization of $90.32 billion, a price-to-earnings ratio of 14.20, a P/E/G ratio of 1.09 and a beta of 0.84. The company has a 50 day moving average price of $387.20 and a 200 day moving average price of $465.15.

Elevance Health Profile

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.